Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

Commentary
Video

Kimberly A. Spickes, CNP, discusses how often patients with endometrial cancer have dose reductions or interruptions at her institution, and who is involved in the decision to dose-reduce.

Recent Videos
Gynecologic Cancers
Related Content
Image of the female reproductive system with tumor growth on the uterine lining

Real-World Data Verify Safety/Efficacy of Dostarlimab/Chemo in Endometrial Cancer

Jax DiEugenio
March 26th 2025
Article

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by results of a real-world study.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Person's hand holding a prescription bottle of olanzapine

Olanzapine May Address AEs From TKIs for Kidney and Other Cancers

Darlene Dobkowski, MA
February 17th 2025
Article

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

light blue background with a white outline indicating a clipboard that says FDA

FDA Grants Breakthrough Status to Endometrial Cancer Assay

Kyle Doherty
February 9th 2025
Article

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.

yellow background with a white outline indicating ovaries and other gynecological structures

Azenosertib Demonstrates Activity and Tolerability in Ovarian Cancer

Ashling Wahner
February 2nd 2025
Article

Azenosertib (ZN-c3) demonstrated activity as a single agent in heavily pretreated patients with platinum-resistant, cyclin E1-positive ovarian cancer.